Sorl Auto Parts, Inc. (NASDAQ:SORL) Raises Guidance after Stellar Q3

Sorl Auto Parts, Inc. (NASDAQ:SORL)

Shares of Sorl Auto Parts, Inc. (NASDAQ:SORL) gained 20.4% after the leading manufacturer and distributor of automotive brake systems reported Q3 financial results that beat Wall Street estimates. According to the Chief Executive Officer, Xiaoping Zhang, demand for the company’s products continue to increase across all three business segments.

Sorl Auto Parts, Inc. (NASDAQ:SORL)

Sorl Sales Growth

Investors reacted to the better than expected financial results by pushing the stock up the chart, after coming under pressure in recent weeks. The stock is currently trading in an uptrend with immediate resistance at $8.40, above which it could make a push for the 52-week high of $9.74 a share. For the full year, the stock is up by more than 90%.

For the three months ended September 30, 2017, Sorl Auto Parts, Inc. (NASDAQ:SORL) generated sales of $101.3 million – representing a 59% year over year growth. Revenues from international markets increased 19.1% to $19.3 million due to growing global customer base. Net sales for the first nine months of the year increased 29.6% to $72.9 million.

Gross profit in the quarter grew 44.4% to $27.3 million compared to $18.9 million reported last year. However, gross margin dropped to 26.9% from 29.7% due to higher raw materials costs and price promotion designed to increase market share.

“We are excited to report that our sales growth in all three segments accelerated during the quarter. We continue to capture market share in the Chinese commercial vehicle braking market with our new advanced products and attractive pricing,” said Mr. Zhang.

New Guidance

Net income attributed to shareholders increased 165% to $8.6 million or $0.44 a share compared to $3.2 million or $0.17 a share reported last year. Net income for the first nine months of the year nearly doubled to $21.4 million or $1.11 a share from $10.9 million or $0.57 a share reported last year.

Sorl Auto Parts, Inc. (NASDAQ:SORL) exited the third quarter with cash and cash equivalent of $7.6 million. Inventories in the quarter increased to $83.1 million from $65.8 million as of December 31, 2018.

Buoyed by the strong performance in the third quarter, Sorl Auto Parts, Inc. (NASDAQ:SORL) management has increased its full-year guidance for net sales, from $315 million to approximately $370 million. The company also expects net income of $30.5 million up from an initial guidance of $27.5 million.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $SORL and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

Why Anthera Pharmaceuticals Inc (NASDAQ:ANTH) Jumped

Anthera Pharmaceuticals Inc (NASDAQ:ANTH)

Anthera Pharmaceuticals Inc (NASDAQ:ANTH) shares closed up 10%, and had two closing days above the $2 level for the first time since May of 2017. The catalyst for the stock’s upward momentum, on a day when markets sold off, seems to be an article authored by a CFA specializing in the biotech space. The analyst rates the shares a “Buy”.

Anthera Pharmaceuticals Inc (NASDAQ:ANTH)

Anthera Pharmaceuticals Inc (NASDAQ:ANTH) is a biopharmaceutical company that develops and commercializes therapies to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. Anthera has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod. Sollpura is a non-porcine investigational Pancreatic Enzyme Replacement Therapy intended for the treatment of patients suffering from Exocrine Pancreatic Insufficiency, often seen in patients with cystic fibrosis.

Analysts on Anthera

Three analysts follow Anthera Pharmaceuticals Inc (NASDAQ:ANTH). One rates ANTH as a “Strong Buy”, while the other two rate the shares as a “Hold”. The analysts have a consensus, one-year price target of $2.00 on the shares – $0.31 below today’s close. For FY2017, analysts are projecting an EPS loss of (-$3.34).

ANTH Stock Performance

For the year, ANTH stock is down over 85%. However, the shares are up 45% for the past month.

In 2015, Anthera posted sales of $3.2 million but for 2016 the figure was a disappointing $100,000. Earnings have been disappointing as well. In 2012, the biotech firm reported an earnings loss of (-$50.19). The next year the loss was (-$13.52), followed in 2014 by a loss of (-$10.88), then (-$7.91) for 2015, and in 2016, the loss was (-$12.87).

There are a number of short-sellers on ANTH stock. Their short positions represent 15% of the stock’s float.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ANTH and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

Quest Resource Holding Corp (NASDAQ:QRHC)

Quest Resource Holding Corp (NASDAQ:QRHC) Makes Large Gains

Quest Resource Holding Corp (NASDAQ:QRHC)

Quest Resource Holding Corp (NASDAQ:QRHC) stock has gained over 70% after the waste management company released their Q3 2017 earnings report. QRHC shares gapped up to open at $1.48, then continued to rise to $2.91 before sellers stepped in. QRHC stock has been trading in a range between $1.90 and $2.10 since 10:30 AM EST. Volume is enormous. The stock normally trades about 38,000 shares per day, but with two hours left in today’s trading session, over 6.1 million shares have exchanged hands.

Quest Resource Holding Corp (NASDAQ:QRHC)

Quest Resource Q3 Financial Report

EPS for Q3 2017 was forecast by analysts at (-$0.07) and that is exactly what the company reported. Net loss improved by $1.3 million to (-$1.1) million compared with a net loss of (-$2.4) million for the third quarter of 2016. During the third quarter of 2017, operating expenses were $5.0 million, a decrease of $1.0 million, or 16%, compared with the third quarter of 2016. Adjusted EBITDA improved by $786,000 to $513,000 compared with a loss of (-$273,000) for Q3 2016.

Quest Resource Holding Corp (NASDAQ:QRHC) provides recycling and disposal services for a range of waste streams and recyclables generated by businesses. The company also operates social media and online digital platforms that contain information and instructions to recycle or properly dispose of household products and materials. Its services focuses on the waste streams and recyclables from big box, food chain, and other retailers.

QRHC Stock Performance

Year-to-date, QRHC stock is down over 50%. However, two investment forms cover Quest Resource Holding Corp (NASDAQ:QRHC) and both rate the shares as a “Strong Buy” with a consensus, one-year price target of $6.00. The stock’s 52-week low is $1.03, and its 52-week high is $3.00.

Quest Resource Holding Corp (NASDAQ:QRHC) has a market capitalization of less than $20 million but annual sales of over $175 million. Unfortunately, earnings have been challenging. In 2012 is lost (-$5.92) per share, and last year the loss was a more modest (-$0.55).

Stock dilution has been an issue for shareholders. In 2012, 7.12 million shares were outstanding. By the end of 2016, that number was 14.74 million.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $QRHC and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Sunshine Heart Inc (NASDAQ:CHFS) Stocks Skyrockets on SEC Filing

Sunshine Heart Inc (NASDAQ:CHFS)

Short-sellers of Sunshine Heart Inc (NASDAQ:CHFS) felt the pain today as the stock rocketed up over 500% in early afternoon trading, but have hit strong resistance at the $25 mark. While there has been no news released concerning the company, reports suggesting a catalyst for the upward move reference an SEC filing for a public offering of preferred stock and warrants.

Sunshine Heart Inc (NASDAQ:CHFS)

The filing details a potential offering of preferred shares and warrants totaling $32 million. The unit offering involves $10 million of preferred shares and $22 million of common shares that would be exercisable by the warrant holder(s). The 10,000 preferred shares would be exercisable into 2.141 million common shares of CHFS. The 22 million warrants could be converted into 4.282 million common shares of CHFS. The pricing of the public offering was not disclosed in the filing. In April, 2017, CHFS stock plunged 30% on the news of a dilutive offering of common shares.

About Sunshine Heart

A cardiac surgeon founded Eden Prarie, MN-based Sunshine Heart, Inc (NASDAQ:CHFS). Sunshine Heart is a medical device company that creates, develops, and commercializes technologies that address heart failure. The EU regulatory authorities have granted a CE Mark to their C-Pulse Heart Assist System. In the USA, the system is undergoing clinical studies to determine its safety and efficacy for the treatment of moderate to severe heart failure.

Sunshine Heart, Inc (NASDAQ:CHFS) lead product is the Aquadex FlexFlow® ultrafiltration system. The Aquadex FlexFlow system removes excess fluid from patients suffering from fluid overload who have failed diuretic therapy. Heart failure is the leading cause of fluid overload. The American Heart Association estimates that 6.5 million people in the United States, age 20 and over, had heart failure. There are an estimated 960,000 new heart failure cases annually. Annual hospitalizations for heart failure exceed 1 million in United States and Europe, and more than 90% are due to symptoms and signs of fluid overload.

CHFS Stock Developments

On October 10, 2017, Sunshine Heart, Inc (NASDAQ:CHFS) stockholders approved, later approved by the Board of Directors, a reverse 1:20 stock split. That move was in response to a notification from The NASDAQ Stock Market LLC informing Sunshine Heart that they were no longer in compliance with the minimum bid price requirement, as the bid price of shares of CHFS common stock closed below the minimum $1.00 per share threshold for 30 consecutive business days. Nasdaq also notified the company that they had 180 calendar days, or until November 28, 2017, to regain compliance.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $CHFS and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

CASI Pharmaceuticals Inc. (NASDAQ:CASI)

CASI Pharmaceuticals Inc. (NASDAQ:CASI) Reports Narrow Q3 Net Loss

CASI Pharmaceuticals Inc. (NASDAQ:CASI)

Shares of CASI Pharmaceuticals Inc. (NASDAQ:CASI) gained 8.37% after the biopharmaceutical company reported a narrower than expected net loss for the three and nine months ended September 30, 2017. In addition, the company was able to strengthen its balance sheet through the issuance of shares to certain investors.

CASI Pharmaceuticals Inc. (NASDAQ:CASI)

Declining Net Loss

Net loss for the third quarter came in at ($1.6) million or (-$0.03) a share, compared to a net loss of (-$1.7) million reported last year. For the first nine months of the year, CASI Pharmaceuticals net loss totaled (-$5.7) million, compared to a net loss of (-$6.8) million reported last year.

CASI Pharmaceuticals Inc. (NASDAQ:CASI) attributes the decline in net loss to a decrease in non-cash compensation expense associated with stock option issuance. Clinical expenses associated with the development of the company’s lead candidate drug ENMD-2076 were also down in the quarter.

“I am pleased with our third quarter financial results. In October, we announced a $23.8 million registered direct offering, funds raised from which will be used to advance our internal pipeline and support our business development in-license activities,” said CEO Ken K. Ren.

CASI Stock Performance

Investors reacted to the declining net loss by pushing the stock up the chart. The stock is currently trading in an uptrend as it makes a push for its 52-week high of $3.18 a share. CASI Pharmaceuticals is up by more than 100% for the year, as it continues to outperform the overall industry.

Data compiled by Zacks Investment Research indicates that the stock is currently rated as a ‘strong buy’ by one analyst firm. Analysts are forecasting a 14.71% year over year increase in earnings this year compared to last year. However, the analysts expect a -6.9% earnings growth next year.

Public Offering

Separately, China’s Food and Drug Administration has granted a priority review for CASI Pharmaceuticals Inc. (NASDAQ:CASI) clinical trial application for EVOMELA for injection. Depending on the review, the company could make a clinical trial application by the end of the year.

In September, CASI Pharmaceuticals Inc. (NASDAQ:CASI) entered into agreements with certain institutional and accredited investors for the purchase of approximately $23.8 million securities in a direct offering. The company expects net proceeds of $23.3 million that is to be used to support business development activities which includes advancing clinical trial programs.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $CASI and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Atossa Genetics Inc. (NASDAQ:ATOS)

Atossa Genetics Inc. (NASDAQ:ATOS) Q3 Earnings Disappoint

Atossa Genetics Inc. (NASDAQ:ATOS)

Atossa Genetics Inc. (NASDAQ:ATOS) fell 4.4% as investors reacted to the company’s third quarter financial results and corporate update. The clinical stage pharmaceutical company did not report any revenue for the three months ended September 30, 2017, as it is in the research and development phase.

Atossa Genetics Inc. (NASDAQ:ATOS)

Atossa’s Pipeline Development

Operating expenses for the quarter totaled $2.1 million and $5.6 million for the first nine months of the year. Research and development expenses in the quarter increased to $0.7 million from $0.1 million reported last year.

During the quarter, Atossa Genetics Inc. (NASDAQ:ATOS) announced preliminary results from a Phase 1 study of its lead candidate drug Endoxifen. The drug met its primary endpoint with no significant safety signal or adverse events.

Atossa Genetics is currently preparing for a Phase 2 study that will evaluate Endoxifen for the treatment of women with mammographic breast density. The study will be conducted in partnership with the Stockholm South General Hospital in Sweden.

“We are very pleased with our recent clinical progress with our Endoxifen programs. Preliminary results from our Phase 1 study show that all objectives of both our proprietary topical and oral formulations of Endoxifen have been met. We recently raised capital to support advancement of our Endoxifen,” said CEO, Steve Quay

Atossa Genetics Inc. (NASDAQ:ATOS) underperformance continued in the market following the third quarter financial results. The stock is currently languishing as it closes in on its 52-week low of $0.32 a share. The stock has shed more than 70% in market value since the start of the year. As it stands, the stock needs a new catalyst if it is to bounce back.

ATOS Public Offering Impact

Declining investor confidence in Atossa Genetics follows the pricing of a public offering of the company’s common shares at a deep discount. The move did not go well with investors. The public offering’s pricing triggered a selloff of the stock to current lows.

Atossa Genetics issued 11.5 million shares of common stock priced at $0.44 a share. The company also offered underwriters the option of purchasing an additional 1 million shares pursuant to the over-allotment option.

Gross proceeds before deduction of underwriting discounts commissions and the offering costs were approximately $5.5 million. Atossa Genetics Inc. (NASDAQ:ATOS) plans to use net proceeds from the offering for general corporate purposes.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ATOS and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Celsion Corporation (NASDAQ:CLSN) Q3 Results Disappoint

Celsion Corporation (NASDAQ:CLSN)

Shares of Celsion Corporation (NASDAQ:CLSN) fell 5.2% after the oncology drug development company reported financial results for the three and nine months ended September 30, 2017. A net loss for the two periods appears to have spooked the market, fuelling a sell-off of the stock.

Celsion Corporation (NASDAQ:CLSN)

CLSN Sell-Off

Following Tuesday’s sell-off, Celsion Corporation (NASDAQ:CLSN) is at risk of dropping to this year’s lows as it continues to trade in a strong downtrend. The stock has shed more than 50% in market value since the start of the year as investors continue to question the company’s long-term prospects.

However, data compiled by Zacks Investment Research indicates that two analyst firms currently rate the stock as a ‘strong buy’ amidst the growing short interest. Despite disappointing financial results, analysts are forecasting a 76.6% year over year increase in earnings. The analysts also expect earnings to grow by 48.4% next year.

For the quarter ended September 30, 2017, Celsion Corporation (NASDAQ:CLSN) reported a net loss of (-$5.7) million or (-$0.70) a share compared to a net loss of (-$6.4) million reported last year. The company attributes the decrease to a tighter clinical development focus coupled with lower operational expenses. Net loss for the first nine months came in at (-$16.1) million compared to (-$16.7) million as of last year.

Celsion Pipeline Development

During the quarter Celsion Corporation (NASDAQ:CLSN) recognized deemed dividends totaling $0.4 million with regards to multiple agreements with certain warrant holders. The company also made important milestones in the development of its lead clinical programs and capital infusion of $38 million to help drive the development efforts.

Celsion Corporation (NASDAQ:CLSN) is currently working on ThermoDox, its proprietary heat-activated liposomal encapsulation currently in Phase III for the treatment of primary liver cancer. The company’s immunotherapy program consisting of GEN-1 is currently in Phase 1 development as a localized treatment for Ovarian Cancer.

“We believe that we now have sufficient capital to complete enrollment of our Phase III OPTIMA Study and through the first efficacy analysis expected in the first quarter of 2019. Further, we expect that our current funds will allow us to make substantial progress in our open-label, randomized, 86 patient Phase I/II study of GEN-1 in newly diagnosed stage III and IV ovarian cancer patients,” said CEO, Michael Tardugno.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $CLSN and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Energy XXI Gulf Coast Inc. (NASDAQ:EXXI)

Energy XXI Gulf Coast Inc. (NASDAQ:EXXI) Drops on Wider Net Loss

Energy XXI Gulf Coast Inc. (NASDAQ:EXXI)

Shares of Energy XXI Gulf Coast Inc. (NASDAQ:EXXI) fell 34.3% after the oil and natural gas exploration and production company reported disappointing third quarter financial results. A net loss of (-$31.6) million or (-$0.95) loss per share, attributed to lower production and losses on derivative financial instruments, did not go well with investors.

Energy XXI Gulf Coast Inc. (NASDAQ:EXXI)

EXXI Stock Performance

Tuesday’s sell-off resulted in Energy XXI Gulf Coast Inc. (NASDAQ:EXXI) recording a new 52-week low of $5.32 a share as the stock’s downturn shows no signs of slowing down. The stock has underperformed the overall industry for the better part of the year even as the energy sector shows signs of recovery. For the full year, the stock is down by more than 80% as it continues to trade in a strong downtrend.

Energy XXI Gulf Coast Inc. (NASDAQ:EXXI) underperformance has already caught the attention of analysts. According to data compiled by Zacks Investment Research, analysts are forecasting earnings increase of 0% this year, over last year. Next year earnings on the other hand should increase 21.1%

Total revenues for the third quarter totaled $117 million inclusive of a $12.5 million loss on derivative financial instruments. Second quarter revenues totaled $143.7 million. Total LOE in the quarter was $77.8 million per BOE, made up of $64.3 million in lease operating expense. According to the Chief Executive Officer, Douglas E. Brooks, reduction of LOE and G&A costs resulted in a 45% improvement in adjusted EBITDA quarter over quarter.

Commodity Hedging

The natural gas exploration and development company entered into fixed price swap contracts benchmarked to NYMEX-WTI to hedge 8,000 BOPD of production for the full year. The swap contracts are priced at $50.68. The company also has fixed price swap contracts benchmarked to LLS-Argus for 2,000 BOPD with an average fixed price of $55.45 for the January to June 2018 period.

Energy XXI Gulf Coast Inc. (NASDAQ:EXXI) is currently working with its financial advisors on it’s long-term strategic plan focused on the Gulf of Mexico consolidation

“Since no executable combination has resulted from these discussions, we are now focused on our stand-alone options, which include a drilling program beginning in early 2018. This activity in 2018 and beyond may be funded internally through existing liquidity, the benefit of higher oil prices, and continued progress on reducing costs,” said Mr. Douglas E. Brooks.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $EXXI and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

MoSys Inc. (NASDAQ:MOSY)

MoSys Inc. (NASDAQ:MOSY) Spikes

MoSys Inc. (NASDAQ:MOSY)

MoSys Inc. (NASDAQ:MOSY) shares have spiked over 140%, to $1.60, on the back of massive volumes after the technology company reported Q3 2017 financial results. Volume has been huge. Currently, over 127 times the average share volume has traded today.

MoSys Inc. (NASDAQ:MOSY)

MoSys, Inc. (NASDAQ:MOSY) is a nano-cap ($5.4 million) fabless semiconductor company enabling leading equipment manufacturers of Cloud, networking, communications, and data center systems to address the continual increase in Internet users, data and services. The company’s solutions deliver data path connectivity, speed and intelligence while eliminating data access bottlenecks on line cards and systems scaling from 100G to multi-terabits per second.

MoSys Q3 Earnings

MoSys, Inc. (NASDAQ:MOSY)’s Q3 2017 net loss was $1.7 million, or ($0.22) per share, compared with a net loss of $4.0 million, or ($0.60) per share, for the previous quarter and a net loss of $4.7 million, or ($0.71) per share, for the same period in 2016. Total net revenue for Q3 2017 was $2.5 million, compared with $1.4 million for the previous quarter and $1.6 million for the third quarter of 2016. Product revenue for the third quarter was $2.2 million, compared with $1.1 million in the second quarter of 2017 and $1.2 million in the year-ago period.

Len Perham, President and CEO of MoSys, Inc. (NASDAQ:MOSY), “Our revenue growth in the third quarter was primarily driven by increased shipments to our largest Bandwidth Engine 2 customers. More specifically, the design wins with our lead security-appliance customer entered production in early 2017, and have been a significant driver of our increased revenue this past year. As part of our close collaboration with our lead customers, we have developed a solid backlog that extends out through 2018.”

MOSY Stock Performance

The consensus of analysts gave shares of MoSys, Inc. (NASDAQ:MOSY) a one-year price target of $2.00. That level has not been reached since late June, after which MOSY shares began a slide that saw the shares trade under the important $1 level for the majority of the trading sessions since the beginning of September.

MOSY shares have drastically underperformed the sector and market over the past year. Year-to-date MOSY shares are down over 70%. Over the past month, shares have dropped over 20%. Despite the poor performance, today’s spike has moved MOSY’s Relative Strength Index score to 83 – a figure well above the threshold normally considered for labeling a stock as “overbought”.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $MOSY and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Marrone Bio Innovations Inc (NASDAQ:MBII)

Mixed Financial Results for Marrone Bio Innovations Inc (NASDAQ:MBII)

Marrone Bio Innovations Inc (NASDAQ:MBII)

Marrone Bio Innovations Inc (NASDAQ:MBII) (MBI) reported a Q3 2017 EPS loss of (-$0.27) against a consensus analyst estimate of (-$0.24), and a loss of (-$0.29) for Q3 2016. However, revenues increased 16%, and gross margins increased by 41% which has fueled a 11% gain in late-morning trading.

Marrone Bio Innovations Inc (NASDAQ:MBII)

Dr. Pam Marrone, CEO of Marrone Bio Innovations Inc (NASDAQ:MBII), made a statement regarding the company’s performance and future prospects “We experienced several noteworthy catalysts in the third quarter of 2017… Despite these major events, unfavorable weather conditions reduced the number of expected sprays in several of our key markets. Historically, the third quarter produces the lowest sales of the year and is the most unpredictable, evidenced by hurricanes Irma and Maria which significantly impacted our sales in Florida and Puerto Rico.”

Marrone Bio Innovations Inc (NASDAQ:MBII) develops and distributes pest management solutions on a global scale. Marrone Bio’s help customers operate more sustainably while improving plant health and increasing crop yields. The company currently has six commercially available products (Regalia®, Grandevo®, Venerate®, Majestene®, Haven™ and Zequanox®), with Stargus™ planned for launch later in 2017 as well as seven other product candidates in various stages of the company’s rapid development pipeline.

Marrone Bio Developments

The company received EPA registration for MBI-110 (Stargus) for specialty crops and Amplitude for row crops. MBI plans to launch Stargus in the United States market in 2017. As part of MBI’s collaboration with Evogene, transgenic plants carrying MBI’s insecticidal genes were developed and one candidate showed promising results (100% kill) against cabbage looper. Additional tests are in progress. Finally, the company signed new distribution agreements in Africa with regionally significant firms such as ÉLÉPHANT VERT in North Africa and Kenya Biologics in Kenya and Tanzania.

MBII Stock Performance

MBII stock dropped from the $2.50 level in late 2016, then met strong support at the $1 mark. Over the years, the company’s EPS and sales figure have trended positively. In 2012, the company had an EPS loss of (-$10.36). In the years that followed, losses continued by at smaller amounts. In 2016 the EPS loss was (-$1.26). Sales have trended upwards since 2012 when the company reported $7.1 million. By 2016 that number improved to $14 million.

The consensus of analyst gives MBII stock a one-year price target of $2.50. However, the stock’s 52-week high is $2.61. Three investment firms follow Marrone Bio Innovations Inc (NASDAQ:MBII). One rates MBII shares as a “Strong Buy” while two rate the stock as a “Hold”.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $MBII and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.